Form 4: ADMA Director Guiheen Boosts Stake with RSUs, Options

ADMA Biologics Director Lawrence P. Guiheen increased his beneficial ownership through the acquisition of restricted stock units and stock options.

Summary

• Lawrence P. Guiheen, a Director of ADMA Biologics, Inc. (ADMA), reported an acquisition of 10,690 Restricted Stock Units (RSUs) at a price of $0 on February 9, 2026.
• These RSUs will vest in two equal installments, on the sixand 12-month anniversaries of the grant date, becoming fully vested on February 9, 2027, subject to continued service.
• Guiheen also acquired 17,730 stock options with an exercise price of $16.37 on February 9, 2026, which will vest in twelve equal monthly installments, becoming fully vested on February 9, 2027, and expire on February 9, 2036.
• Following these transactions, Guiheen directly beneficially owns 105,520 shares of common stock, which includes the newly granted RSUs, 5,445 RSUs from a prior grant (vesting February 19, 2026), and 89,385 shares of common stock.
• Additionally, Guiheen indirectly beneficially owns 50,990 shares of common stock held in the Lawrence P Guiheen Irrevocable Trust 1.
• The total number of derivative securities beneficially owned after the reported transaction is 17,730 stock options.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as it represents an increase in a director's stake, aligning their interests with shareholders, even if it's part of a compensation package rather than an open-market purchase.

Positives

• A Director increasing their beneficial ownership, even through grants, generally signals continued alignment of interests with shareholders and confidence in the company's future prospects.
• The acquisition of stock options provides a long-term incentive for the Director to contribute to the company's stock price appreciation, as the options have an exercise price of $16.37 and expire in 2036.

Risks

• The vesting of both the RSUs and stock options is contingent upon the Reporting Person's continued service to the company as of the applicable vesting dates.

Future Outlook

The grants of RSUs and stock options include vesting schedules extending to February 2027, indicating a continued commitment and alignment of the Director's interests with the company's long-term performance.

Industry Context

StockSavvy.ai notes that the granting of restricted stock units and stock options is a standard component of executive and director compensation packages across the biotechnology and pharmaceutical industries. These equity awards are designed to align the interests of management with those of shareholders by tying a portion of their compensation to the company's stock performance and long-term value creation. This particular filing reflects a routine compensation event rather than an open-market purchase or sale.

Related Party Transactions

• 50,990 shares of common stock are held indirectly in the Lawrence P Guiheen Irrevocable Trust 1.

Stakeholder Impact

• Shareholders may view the increased beneficial ownership by a director as a positive indicator of management's confidence in the company's future, potentially fostering investor trust.
• The vesting schedules for RSUs and options incentivize the director to contribute to the company's long-term success, benefiting all stakeholders.

Next Steps

• The 10,690 RSUs will vest in two equal installments on the sixand 12-month anniversaries of the grant date (February 9, 2026), becoming fully vested on February 9, 2027.
• The 17,730 stock options will vest in twelve equal monthly installments, becoming fully vested on February 9, 2027.
• The remaining 5,445 RSUs from a prior grant (February 19, 2025) will vest fully on February 19, 2026.

Key Dates

Keywords

ADMA Biologics, Form 4, Insider Transaction, Restricted Stock Units, Stock Options, Director Compensation, Beneficial Ownership, Equity Grant